Session Type: ACR Concurrent Abstract Session
Session Time: 2:30PM-4:00PM
Background/Purpose: Cardiovascular risk in patients with psoriatic disease is partly attributed to the high prevalence of traditional cardiovascular risk factors in these patients. This study aimed to estimate the proportion of under-treatment of cardiovascular risk factors in an international multicentre cohort of patients with psoriasis and psoriatic arthritis (PsA).
Methods: A cross-sectional analysis of patients with psoriatic disease from the International Psoriasis and Arthritis Research Team (IPART) cohort was conducted. The presence of traditional modifiable cardiovascular risk factors (diabetes, hypertension, dyslipidemia, smoking and central obesity) and the use of appropriate therapies were determined based on patients’ report, physical examination and laboratory tests. The 10-year cardiovascular risk was calculated according to the Framingham Risk Score (FRS). Adherence with guidelines for the treatment of dyslipidemia (Stone et al. Circulation 2014;129:S1-45) and hypertension (James et al. JAMA 2014;311:507-20) was assessed. Chi-square and Cochran-Armitage trend test were used to compare categorical variables across groups.
Results: A total of 2254 patients (58.9% PsA, 41.1% psoriasis alone) from 8 centres in Canada, US and Israel were included. Their mean age was 52±13.8 years and 53% were males. 83.2% of the patients had at least one modifiable cardiovascular risk factor. Based on the FRS classification 30% of patients were in a high risk and 18% were in a moderate risk category. 6.1% of the patients had ischemic heart disease, 45.1% hypertension, 71.1% dyslipidemia, 12.6% diabetes, 54.3% central obesity and 17.3% were current smokers. A significant proportion of under-treatment of hypertension and dyslipidemia was found. 455 (20.4%) patients had uncontrolled blood pressure (43% of them were not on antihypertensive medications). Uncontrolled hypertension was associated with low level of education (p<0.001) and severe psoriasis (PASI≥10, p<0.001). 850 (37.9%) patients had an indication for statin therapy but were not using these medications. Under-treatment of dyslipidemia was more frequent in patients with PsA (p=0.005), those with low-level of education (p<0.001) and patients with severe psoriasis (p=0.03).
Conclusion: In a real-world setting, a large proportion of patients with psoriasis and PsA were undertreated for hypertension and hyperlipidaemia.
To cite this abstract in AMA style:Eder L, Chandran V, Rosen C, Dutz J, Elder JT, Rahman P, Ritchlin CT, Tausk FA, Rohekar S, Hayday R, Barac S, Zisman D, Feld J, Gladman DD. Under-Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease – an International Multicentre Study [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/under-treatment-of-cardiovascular-risk-factors-in-patients-with-psoriatic-disease-an-international-multicentre-study/. Accessed December 6, 2019.
« Back to 2015 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/under-treatment-of-cardiovascular-risk-factors-in-patients-with-psoriatic-disease-an-international-multicentre-study/